Last reviewed · How we verify
NCT06729320
A Randomized Controlled, Open, Single-center Clinical Study Evaluating the Efficacy and Safety of Umbilical Cord Blood Mononuclear Cells in Patients with Refractory Immune Effector Cell-related Hemocytopenia
NA trial testing Umbilical cord blood mononuclear cells in Refractory Immune Effector Cell-related Hemocytopenia in 40 participants. Not yet recruiting.
1 June 2025
Quick facts
| Lead sponsor | Beijing GoBroad Hospital |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 1 December 2024 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Umbilical cord blood mononuclear cells — full drug profile →
- Conventional hematopoietic recovery therapy
Conditions studied
- Refractory Immune Effector Cell-related Hemocytopenia — all drugs for Refractory Immune Effector Cell-related Hemocytopenia →
Sponsor
Beijing GoBroad Hospital
Who can join
18 and older, any sex, with Refractory Immune Effector Cell-related Hemocytopenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to evaluate the safety and efficacy of umbilical cord blood mononuclear cell in the treatment of refractory immune effector cell-related hemocytopenia by observing the efficacy related factors and adverse reactions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06729320
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Umbilical cord blood mononuclear cells
Trials testing the same drug.
- NCT04997590 — Clinical Study of Umbilical Cord Blood Mononuclear Cells (UCB-MNCs) in the Treatment of Traumatic Fracture Healing · NA · unknown
Other Beijing GoBroad Hospital trials
Trials by the same sponsor.
- NCT07520357 — A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinom · Phase 2 · not yet recruiting
- NCT06947473 — Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. · Phase 1, PHASE2 · recruiting
- NCT06326008 — Safety, Tolerability, and Pharmacokinetics of Donor-derived CD19 CAR Therapy Bridged Allo-HSCT and Sequential Donor-deri · Phase 1 · recruiting
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07179484 — To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06729320 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing GoBroad Hospital
- Last refreshed: 11 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06729320.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing